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Abstract 
Annexins and protein kinases C belong to two distinct families of ubiquitous cytoplasmic proteins involved in signal transduction. All 
annexins hare the property of binding calcium and phospholipids in the presence of calcium. Protein kinases C belong to three distinct 
groups of kinases: cPKCs (conventional PKCs) depend on calcium, diacylglycerol and negatively charged phospholipids for their activity, 
nPKCs (novel PKCs) depend on diacylglycerol and negatively charged phospholipids and aPKCs (atypical PKCs) only require negatively 
charged phospholipids. Almost all annexins are both in vitro and in vivo substrates for PKCs except annexin V. All annexins have a 
putative binding site for PKCs but only annexin V would possess apotential pseudo-substrate site. We propose that annexin V modulates 
the activity of some cPKCs on their substrates which may be the other annexins. 
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1. Introduction 
Annexins and cPKCs share numerous common proper- 
ties but mainly they are both sensitive to calcium and 
negatively charged phospholipids, they both interact with 
the cytoskeleton and translocate to the membrane upon cell 
activation [1]. Complex relationships could occur between 
these two families of proteins and they could interact 
during signal transduction i volving PKCs. 
2. The annexins 
Annexins form a family of protein, discovered in the 
eighties, comprising at this day 18 members in different 
species and up to 10 members in the mammalian world 
[2-4]. To belong to the annexin family, two criteria are 
required: (1) a biological one: the protein binds to millimo- 
lar amounts of calcium alone and to phospholipids in the 
presence of micromolar amounts of calcium; and (2) a 
structural one: the core of the protein is formed by the 
repeat (4 times for most annexins and 8 times for annexin 
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VI) of a conserved omain of 70 amino acids in which is 
found the canonical sequence of annexins. These proteins 
have been implicated in numerous physiological functions 
all involving membrane and calcium; nevertheless the 
exact roles of annexins are far from being understood. 
Some annexins could be involved in signalling path- 
ways. One putative role could be the transmission of 
information from the membrane to the cytoskeleton and/or 
to other cytoplasmic omponents. Some annexins have 
been reported to bind actin in the presence of calcium (A-I, 
A-II, A-VI), fodrin, cahnodulin. Some annexins are the 
substrates of protein tyrosine kinases (A-I, A-II), and of 
protein kinases C (AI-AIV, A-VI, A-XII). The phosphory- 
lation of annexins I and II is calcium- and phospholipid- 
dependent. Indeed, annexins, through their interactions 
with the cytoskeleton and their phosphorylations could 
play a role during cell activation in some yet unknown 
signalling pathways [2]. 
Annexins, as mentioned above, are formed of two 
distinct domains: one N-terminal domain and the C-termi- 
nal domain which is, in the case of annexins, the major 
part of the protein or the core (Fig. 1). The N-terminal 
domain is different for each annexin; it may be very short 
as for annexin V or very long as for annexin VII and 
annexin XI. It is supposed to be responsible for the 
specificity of each member of the annexin family. Indeed, 
it carries the phosphorylation sites and the sites for interac- 
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Fig. 1. Primary ,;tructure of annexins. 
tion with other proteins. The core of the protein, formed of 
4 or 8 (for annexin VI) repeats of a 70 amino acid domain 
harbours a highly conserved 17 amino acid sequence pre- 
sent in all annexins. These domains are necessary for the 
calcium and phospholipid binding properties. 
The 3D structure of five annexins has been solved (A-I, 
All, A-III, A-V, A-XII) and this has allowed visualization 
and analysis of the calcium binding sites [5-9]. Annexin 
cores are formed of four domains only made of alpha 
helices. Each domain is made of five alpha helices (four of 
them are antiparallel: helice.s A, B, D and E and the fifth C 
helice is perpendicular to the others). Between helices A 
and B, and helices D and E are found loops localized at the 
surface of the protein. Calcium ions are found there within 
the loops, coordinated with neighbouring amino acids (as 
determined from the primary sequence) and with the car- 
boxylate group of a negative amino acid (glutamic acid or 
aspartic acid) located 40 amino acids down on the primary 
sequence, but in close proximity on the 3D structure. As 
determined recently, this calcium is responsible for the 
binding of annexins with the polar head of the phos- 
phatidylserine [10]. Theretore, annexin binding to mem- 
branes requires calcium and negatively charged phospho- 
lipids. The N-terminal domain of annexins is located on 
the other side of the mole.cule and thus, phosphorylation 
sites are facing the cytoplasm when annexins are bound to 
membranes. 
Annexins are found under two forms within the cells: 
one part is membrane-associated, whereas the rest of the 
protein is cytosolic. The location is different for each 
annexin; for example, annexins I and II are found in closer 
vicinity to the membranes than annexin V that is essen- 
tially cytoplasmic. All annexins are capable of translocat- 
ing to the membranes; it can be proposed that two factors 
are responsible of their translocation: a calcium increase 
and the appearance of ne~;atively charged omains in the 
membranes. It is also possible that other factors regulate 
their translocation. 
3. The protein kinases C 
PKCs are protein kinases, specific for serine or threo- 
nine, formed of one single polypeptidic hain of 80 kDa 
[11-13]. PKCs are classified in three groups according to 
their structural and enzymatic properties. The first group, 
conventional PKCs (cPKCs) composed of the e~, [31, BII 
and y isoforms require calcium, diacylglycerol and nega- 
tively charged phospholipids for their kinase activity; the 
second group of novel PKCs (nPKCs) G, e, 0, "q require 
diacylglycerol and negatively charged phospholipids and 
the third group of atypical PKCs (aPKCs), ~, h, Ix only 
require negatively charged phospholipids. It should be 
noted that the n and aPKCs do not require calcium for 
their catalytic activity. All PKCs share the same catalytic 
domain and ATP binding site; they differ in their N-termi- 
nal domain that regulates the catalytic domain and carries 
the calcium and diacylglycerol binding sites (Fig. 2). 
The regulatory domain of PKCs contains a pseudo-sub- 
strate sequence, present in all different isoforms of the 
PKCs, this sequence should be responsible of maintaining 
PKCs under an inactive configuration. This sequence is 
similar to the consensus equence of the PKCs substrates 
target sites except hat this pseudo-substrate sequence does 
not have threonine or serine replaced by alanine. In addi- 
tion, the regulatory domain of PKCs contain domains that 
are specific for each group of PKCs and that could be 
responsible of the substrate specificity of each isoform of 
the three groups of PKCs. 
The cPKCS are the only PKCs that possess a calcium 
and phospholipid binding domain (named C2) which is 
also found in synaptotagmin, i  cytosolic phospholipase 
A2, in GAP, in PI-PLCs, in PI3 kinase [14,15]. cPKCs 
translocate from the cytosol to the membranes upon activa- 
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Fig. 2. Primary structure of the different families of  protein kinases C: 
cPKCs (conventional PKCs); nPKCs (novel PKCs) aPKCs (atypical 
PKCs). 
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tion by calcium, diacylglycerol r phorbol esters. More- 
over, the activity of cPKCs require that negatively charged 
phospholipids are present. 
Recently, the 3D structure of the C2 domains of synap- 
totagmin [14] and of PLC-81 [15] have been solved. The 
structure of these domains how that four aspartate r sidues 
coordinate a calcium ion. These residues, suggested to be 
the calcium-mediated lipid binding site, belong to two 
loops located on one side of the molecule. In annexin V, 
the recognition site for the head group of phosphatidylser- 
ine is somewhat similar and consists of two adjacent 
calcium binding sites [10]. 
Moreover, membrane-associated proteins that could be 
receptors for activated PKCs have been identified as 
RACKs (receptor for activated C kinases). These RACKs 
could be specific binding proteins for PKCs and play a 
role in the protein kinase translocation to membranes 
[16,17]. 
4. Inhibition of PKCs 
Endogenous inhibitors for PKCs have been isolated 
from rat [18] and sheep [19] brains, from neutrophils [20]. 
A inhibitory activity for PKCs has also been reported in 
Jurkat cells [21]. More recently, annexin V has been 
proposed as an inhibitor of PKCs [22-26]. 
5. Annexins/protein kinases C relationships 
Among the endogenous inhibitors of PKCs isolated 
from sheep brain [19], one protein of a molecular weight of 
29-33 kDa and homologous to the 14-3-3 family named 
KCIP-1 (protein kinase C inhibitory protein-l) has been 
described [27]. This protein, as well as some other iso- 
forms of the 14-3-3 family, possesses a potential pseudo- 
substrate sequence starting at Gly54 that could explain 
their inhibitory activity on PKCs [28], but Jones et al. [29] 
did report that the introduction of a serine residue at the 
proposed site of phosphorylation did not make a good 
substrate for PKC and the introduction of glutamic residue 
did not increase the cofactor independence of PKC (as is 
seen when Glu is introduced into the pseudosubstrate site 
of PKC itself). More interestingly, these inhibitors bind 
PKCs and have a 16 amino acid homologous equence 
with the 14 last amino acids of annexins (named the 
'annexin-like domain') (Fig. 3), raising the possibility of a 
specific interaction of annexins with PKCs. In relation 
with this hypothesis, annexin I has been shown to bind to 
activated PKCs and proposed to be a RACKs, moreover a
peptide identical to this region inhibits binding of RACKs 
proteins to PKCs only in the presence of calcium and 
phospholipids [17]. As already mentioned, RACKS could 
play a role in PKC translocation from cytosol to membrane 
during cell activation and this interaction is partially medi- 
ated by the C2 domain of cPKCs [16,17,30]. 
Recently, it has been shown that annexin V inhibits in 
vitro phosphorylation f annexin I and II [22-26] and of 
histone IIIS [23,26]. We have also demonstrated that both 
placental and recombinant annexin V inhibit phosphoryla- 
tion of annexin I by cPKCs in rat mesangial cell cytosols 
[23]. In these cells, A-I (but not A-II) is the preferential 
substrate of PKCs both in vitro and in vivo [3l]. In 
cytosols of Jurkat cells, annexin II phosphorylation by 
cPKCs is inhibited by A-V. A-V inhibits also the phospho- 
rylation of other cPKCs substrates [22]. In both cell types 
A-V does not inhibit the phosphorylation of the other 
groups of PKCs (nPKCs and aPKCS). Annexin V as 
KCIP-1 has a potential pseudosubstrate site Arg122- Ala- 
Ile-Lys125 exposed to solvent and located on the surface 
of the protein opposite the face that binds calcium and 
KCIP-1 NH2 
14-3 -3  
annexln NH2 
54-57 127-142 Protein 14.3-3 
230 
|1| 
V! 
amne~lns VII 
VIII 
Xlll 
Fig. 3. PKC binding domain of annexins and of KCIP-1. 
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phospholipids [6]. Annexin V possesses the C-ter annexin 
domain that binds PKCs in RACKs and in KCIP-1. In both 
families of proteins, this domain is accessible for PKCs: it 
is located near the surface of annexin V facing the cyto- 
plasm [6] and it is located at the base of the channel of the 
14-3-3 protein [32]. 
Proposed mechanism of inhibition ] 
6. Mechanisms of inhibition 
6.1. Could the inhibition be the consequence of a competi- 
tion for the phospholipid and calcium binding site? 
Annexins and PKCs share in common their ability to 
bind negatively charged phospholipids in the presence of 
calcium. Inhibition could well be the consequence of a 
competition between cPKCs and annexin V for their mem- 
brane binding site but the ,same calcium and phospholipid 
binding sites are present on annexins I and II. This hypoth- 
esis has been well analysed by Raynal et al. [24] who 
proposed that annexin V inhibition of annexin I PKC-in- 
duced phosphorylation was overcome by increasing the 
concentration of phosphatiidylserine and that this model 
fitted well with the 'surface depletion model' explaining 
the antiphospholipase A2 effect of annexins; they also 
proposed that annexin I and V competed near the lipid 
surface and that annexin V being more abundant han 
annexin I inhibited its phosphorylation. Nevertheless, their 
data do not permit elimination of the possibility that 
another mechanism may be involved such as a direct 
interaction or a pseudo-substrate effect. 
6.2. Could the inhibition be the consequence of the pres- 
ence of a pseudo-substrate s quence in annexin V and//or 
a direct interaction? 
As reported above, the PKC inhibitor KCIP-1 possesses 
the 16 amino acid domain suggested to bind PKCs as 
annexin V [27]. In addition KCIP-1 also presents a PKC 
pseudo-substrate-like domain that would explain the inhi- 
bition of PKCs by KCIP-1. By analogy, it could be 
postulated that annexin V, the only annexin that possesses 
both the binding domain and the pseudo-substrate-like 
domain, could inhibit PKCs in a similar manner to KCIP-1. 
Such a hypothesis has been proposed by Schlaepfer et al. 
[25] who did not find in ~:heir experimental conditions a 
sequestration of phosphatidylserine by annexin V. Never- 
theless, they proposed that a direct interaction between 
annexin V and PKC was involved but they did not demon- 
strate it. 
7. Discussion 
Our data together with those of other groups do not 
allow us to conclude that either mechanism of inhibition is 
II 
PKC 
Fig. 4. Proposed mechanism of inhibition of cPKCs by annexin V on its 
substrate: annexin I or II (see text for legend). 
predominant. Nevertheless, according to the literature, and 
to the knowledge of the structure of the C2 domain and to 
the analogy of the mechanism of inhibition of annexin V 
with that of the 14-3-3 protein, KCIP-1, we propose a dual 
mechanism involving both a competition for phos- 
phatidylserine and a direct interaction. Indeed inhibition of 
cPKCs could be mediated by (1) a competition for the 
phospholipid and calcium binding sites through the C2 
domain that is present only on cPKCs and (2) a direct 
interaction between annexin V and PKCs through the C-ter 
annexin-like domain. Both our group (unpublished ata) 
and that of Aitken [29] have eliminated the pseudo-sub- 
strate hypothesis as responsible of the PKC inhibition. In 
order then to reconcile the two potential mechanisms of 
inhibition, we propose that the specificity of inhibition of 
annexin V towards cPKCs (while annexin I and II are not 
inhibitory but are substrates) could be the consequence of 
the relative concentration of all partners in the vicinity of 
the membrane occurring in a spatio-temporal manner. A 
possible scenario (Fig. 4) could be: annexins I or II are in 
low concentration and are already located in close proxim- 
ity of the membrane; upon cell activation, cPKC is translo- 
cated to the membrane and requires for its full activation 
to be attached to the membrane at least through its C2 
domain: cPKC at a higher concentration than annexin I or 
II can compete in a first time with the membrane binding 
site of annexins I or II and phosphorylate the present 
annexin. Annexin V, which is ubiquitous, whose concen- 
tration in cells (such as Jurkat and mesangial cells) is at 
least two or three orders of magnitude higher that annexin 
I or II, would arrive at the membrane site through the 
binding to cPKCs and could compete for the C2 domain 
membrane binding site of cPKCs and inhibit its kinase 
activity by interrupting the membrane attachment of cPKC 
required for its activation. This would explain why annexin 
V inhibits only cPKCs and has no preference for a sub- 
strate that could be annexins I or II or other proteins. 
Another possibility that could explain the specificity of 
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annexin  V for cPKCs could be the occurrence or another 
yet unident i f ied partner. Further  exper iments  are required 
to understand the exact mechan ism of  inhibit ion of  an- 
nexin V on cPKCs and the re levance of this inhibit ion in 
physio logical  condit ions. 
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